How effective is compound 50 against cancer?
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Effectiveness of Compound 50 Against Cancer
Introduction to Compound 50 and Its Mechanism of Action
Compound 50, also known as FN-1501, is a promising anticancer agent that has shown significant potential in preclinical studies. This compound is a derivative of 1-H-pyrazole-3-carboxamide and has been specifically designed to inhibit FLT3 and CDK kinases, which are critical in the proliferation of cancer cells.
Inhibition of FLT3 and CDK Kinases
Compound 50 exhibits potent inhibitory activities against several key kinases, including FLT3, CDK2, CDK4, and CDK6, with IC50 values in the nanomolar range. This inhibition is crucial as these kinases play a significant role in cell cycle regulation and cancer cell proliferation. The compound's ability to inhibit these kinases effectively leads to the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5, which are essential pathways in cancer cell survival and proliferation.
Antiproliferative Activities
The antiproliferative activities of Compound 50 have been demonstrated in MV4-11 cells, a model for acute myeloid leukemia (AML). The compound shows an IC50 value of 0.008 μM, indicating its high potency in inhibiting cancer cell growth. This antiproliferative effect is associated with the induction of apoptosis, a process of programmed cell death that is often defective in cancer cells.
In Vivo Efficacy and Safety
In vivo studies further support the potential of Compound 50 as an effective anticancer agent. In a nude-mouse model with MV4-11 xenografts, Compound 50 induced significant tumor regression at a dose of 15 mg/kg, outperforming the commonly used chemotherapeutic agent cytarabine, which required a higher dose of 50 mg/kg to achieve similar effects. Additionally, acute-toxicity studies in mice revealed that Compound 50 has a higher safety margin (LD50: 186 mg/kg) compared to AT7519 (32 mg/kg), suggesting it could be a safer option for cancer therapy.
Conclusion
Compound 50 (FN-1501) demonstrates high efficacy against cancer, particularly acute myeloid leukemia, through its potent inhibition of FLT3 and CDK kinases, leading to significant antiproliferative and pro-apoptotic activities. Its superior performance in preclinical models and favorable safety profile highlight its potential for further development as a therapeutic agent in cancer treatment.
Sources and full results
Most relevant research papers on this topic